Psychedelic News and Analysis Made Simple for Investors
Psychedelic Invest is a resource for those looking to invest in the burgeoning psychedelic industry.
Track the entire psychedelic market
We’ve developed the first all encompassing index to track the public psychedelic marketplace.
Explore the Index
Just Some of the Data we Cover
Latest News
Market Research
Mar 18
•
3 min read
In a recent digital conversation with ex-CNN host Don Lemon, now shared widely across the internet, Tesla and SpaceX chief Elon Musk candidly discussed his mental health management strategies, including the use of a prescribed ketamine treatment, asserting its positive impact on his professional performance and, by extension, Tesla’s investor value. During this revealing interview,…
Press
Toronto, Ontario–(Newsfile Corp. – March 18, 2024) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (“Red Light Holland” or the “Company”), a company engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe and a premium brand of psilocybin truffles to the…
Mar 18
•
3 min read
Press
SARASOTA, FL, March 18, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has filed a provisional patent application titled ‘Methods and Combinations for Managing Pain’ with the United States Patent…
Mar 18
•
2 min read
Press
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced participation in the upcoming Public Ventures Discovery Day on March 19, 2024 in Dallas, TX. Doug Drysdale, Chief Executive Officer of Cybin will participate in a…
Mar 18
•
2 min read
Press
TORONTO – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) (‘Cybin’ or the ‘Company’), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, is pleased to announce a proposed private placement of 348,837,210 common shares in the capital of the Company at a price of U.S.$0.43 per Common Share representing…
Mar 14
•
5 min read
Press
Clearmind Medicine Inc. announced that it has received approval from the Israeli Ministry of Health to commence its phase I/IIa clinical trial for alcohol use disorder (AUD) patients using the company’s proprietary MEAI-based (5-methoxy-2-aminoindane) CMND-100 oral capsule. The approval, previously announced on February 23, 2024, allows Clearmind to start its pioneering clinical trial. The clinical…
Mar 14
•
3 min read
Press
CALGARY, AB, March 14, 2024 /CNW/ – ATMA CENA Psychedelic Healthcare Solutions (PHS) is a collaboration of ATMA Journey Centers Inc. (“ATMA”), Cena Life Inc., and partners across Canada to advance and expand access to psychedelic-assisted therapy (PaT) through the establishment of a clinic network. ATMA CENA PHS is pleased to announce commencement of the Calgary Clinic operations and its new location in Edmonton. The London and Toronto, Ontario clinic locations…
Mar 14
•
5 min read
Explore the Psychedelic Landscape
Learn more about the psychedelic companies changing the industry.